Clostridium botulinum is a group of bacteria best known as the main source of botulinum neurotoxin, the cause of botulism in humans. There are several types of botulism. Foodborne botulism is caused by consumption of pre-formed toxin, whereas infant/intestinal (adult) botulism and wound botulism are infections involving toxin formation in situ.
The symptoms of botulism are primarily neurological and frequently begin with blurred vision, continuing to a descending bilateral flaccid paralysis, and in severe cases a flaccid paralysis of the respiratory or cardiac muscles. In many countries, equine antitoxin is administered to adults suffering from botulism, although in severe cases full recovery may take months or even years. The fatality rate is approximately 5 to 10% of cases. The economic and medical costs associated with foodborne botulism are extremely high.
Clostridium botulinum is defined solely on the basis of an ability to form botulinum neurotoxin, rather than on phylogenetic relationships. This approach is taken in order to emphasize the importance of neurotoxin formation. As a consequence, however, C. botulinum is a heterogeneous "species" that actually comprises four phylogenetically and physiologically distinct clades, known as C. botulinum Groups I to IV, with the distinction among the groups strong enough to merit treatment as four different species. Proteolytic C. botulinum (C. botulinum Group I) and non-proteolytic C. botulinum (C. botulinum Group II) are responsible for most cases of foodborne botulism.
(Peck et al. 2011 and references therein)
Based on research begun in the 1980s, botulinum toxin has been found useful in an expanding list of medical applications that require the blocking of involuntary muscle contractions, including eyelid twitching and other neurological problems. In the late 1980s, it was found that injection of botulinum toxin had cosmetic dermatological applications (wrinkle reduction) as well. Botulinum toxin entered the cultural mainstream in the United States in the formulation known as Botox®, establishing a new and highly profitable market for a product once known only as the cause of death for unfortunate individuals consuming improperly prepared sausages. (Kopera 2011)
More information on botulism is available from the U.S.Centers for Disease Control and Prevention.
- Kopera, D. 2011. Botulinum toxin historical aspects: from food poisoning to pharmaceutical. International Journal of Dermatology 50: 976-980.
- Peck, M.W., S.C. Stringer, and A.T. Carter. 2011. Clostridium botulinum in the post-genomic era. Food Microbiology 28: 183-191.
Uses for botulinum toxin
Clinical Applications of Clostridium botulinum
Botulinum toxin is produced by anaerobic Clostridium botulinum bacteria and causes a paralysis called botulism. It was known as a deadly form of food poisoning but while this toxin is one of the deadliest on the planet, it also has a variety of clinical indications. In the 1950’s doctors discovered that injecting overactive muscles with small doses of toxin resulted in reduced muscle activity by blocking the release of acetylcholine at the neuromuscular junction3 and thus weakening the affected muscle for 4-6 months. It has since developed into a therapeutic tool. Since its discovery as a muscle inhibitor a variety of uses have been found for botulinum toxin ranging from cosmetic and medicinal aids to biological weapons. The most popular and recognizable use is a cosmetic injectable form (Botox or Dysport) that reduces wrinkles and signs of aging in the face. Local injection of botulinum toxin is also used to treat excessive sweating, cervical and laryngeal dystonia, excessive blinking and crossed eyes, Tardive dystonia, as well as other disorders of the central nervous system which result in lack of muscle control such as Parkinson’s, stroke and multiple sclerosis2. Botulinum toxin is the most common treatment for symptoms of movement disorders2 such as spasmodic torticollis, tics, tremors and dysphonia. Botulinum Toxin A has been effective in treating migraines and headaches and has been shown to improve gait patterns in patients with cerebral palsy who suffer from foot deformities4. Botulinum toxin has a multitude of medical uses but it must used carefully and with control to avoid permanent paralysis or poisoning.
Botulinum toxin has some unfavorable indications as well. Due to its high toxicity and potency, botulinum toxin has great potential for use as a biological weapon1. Great care need be taken when handling or using Botulinum toxin. A single gram of crystalline toxin, evenly dispersed, can kill over 1 million people1. Also due to its deadly toxicity, botulinum toxin can be used as a powerful poison if misused or ingested. As mentioned above, the toxin can cause a deadly form of food poisoning because it is found in soil and thennwhen transmitted in food sources. . Marine animals have even been shown to ingest C. botulinum from shellfish, resulting in contamination of the intestinal tract5 that is then spread to humans through onshore butchering and poor food preparation precautions.
- Works Cited:
- Arnon, Stephen et al. Botulinum toxin as a biological weapon. l,. 2001.The Journal of the American Medical Association. 285.8 (2001): 1059-70.
- Available from: http://www.bt.cdc.gov/agent/botulism/botulismconsensus.pdf
- 2. Truong, DD et al. Current clinical applications of Botulinum toxin. Current Pharmaceutical Design. 15.31 (2009): 3671-80.
- Available from: http://www.ncbi.nlm.nih.gov/pubmed/19925419
- 3. Ward, Anthony B., and Michael P. Barnes. Clinical uses of botulinum toxins.Vol. 1. Cambridge, UK: Cambridge University Press, 2007. 4-6.
- 4. Munchau A and Bhatia KP. Uses of botulinum toxin in medicine today. British Medical Journal. 320.7228 (2000): 161-65.
- Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1128745/
- 5. Leclair, Daniel et al. Distribution of Clostridium botulinum Type E strains in Nunavik, Northern Quebec, Canada..Applied and Environmental Microbiology. 79.2 (2013): 646-54.
- Available From: http://aem.asm.org/content/79/2/646.full?sid=8f7b3094-b9c5-493b-909b-22e6b0b72acf
Description of Clostridium botulinum
|This article may require cleanup to meet Wikipedia's quality standards. The specific problem is: Second paragraph in lead - sentence structure is broken and needs clarification.. (March 2014)|
Clostridium botulinum is a Gram-positive, rod-shaped bacterium that produces several exotoxins. The best known are its neurotoxins, subdivided in types A-H, that cause the flaccid muscular paralysis seen in botulism. They are also the main paralytic agent in Botox. C. botulinum is an anaerobic spore-former, which produces oval, subterminal endospores and is commonly found in soil.
Culture medium, Clostridium botulinum bacteria. Selective environments: 1 - EYA (Egg-Yolk agar) 2 - CBI (C.botulinum Isolation) Clostridium botulinum It is used for Isolating. Alkaline environments more suitable for microbial growth.Bacteria in liquid environments especially the broth containing many parts to liver grows and the amount of 5% glucose and 5% phosphate potassic to the environment Be added to the growth culture was more frequent. Identification of botulism toxin for ELISA and RIA and PHA use.Clostridium botulinum Glucose, fructose, sucrose, maltose and Salysyn fully ferments to greatly. unable to ferment lactose and xylose. Gas production along with fermentation. Lipase test positive but indole and nitrate and urea tests are negative. Proteolytic strains of Clostridium botulinum Parabvtvlynvm also say that these strains to slow milk coagulated and clot resulting digest.
Clostridium botulinum is a rod-shaped microorganism. It is an obligate anaerobe, meaning that oxygen is poisonous to the cells. However, C. botulinum tolerates traces of oxygen due to the enzyme superoxide dismutase (SOD) which is an important antioxidant defense in nearly all cells exposed to oxygen. C. botulinum is only able to produce the neurotoxin during sporulation, which can only happen in an anaerobic environment. Other bacterial species produce spores in an unfavorable growth environment to preserve the organism's viability and permit survival in a dormant state until the spores are exposed to favorable conditions.
In the laboratory Clostridium botulinum is usually isolated in tryptose sulfite cycloserine (TSC) growth media in an anaerobic environment with less than 2% of oxygen. This can be achieved by several commercial kits that use a chemical reaction to replace O2 with CO2. C. botulinum is a lipase positive microorganism that grows between pH of 4.8 and 7 and can not use lactose as a primary carbon source, characteristics important during a biochemical identification.
Clostridium botulinum was first recognized and isolated in 1895 by Emile van Ermengem from home cured ham implicated in a botulism outbreak. The isolate was originally named Bacillus botulinus, after the Latin word for sausage, botulus. ("Sausage poisoning" was a common problem in 18th and 19th century Germany, and was most likely caused by botulism) However, isolates from subsequent outbreaks were always found to be anaerobic spore formers, so Ida Bengston proposed that the organism be placed into the genus Clostridium as the Bacillus genus was restricted to aerobic spore-forming rods.
Since 1959 all species producing the botulinum neurotoxins (types A-G) have been designated C. botulinum. Substantial phenotypic and genotypic evidence exists to demonstrate heterogeneity within the species. This has led to the reclassification of C. botulinum type G strains as a new species Clostridium argentinense.
The current nomenclature for C. botulinum recognises four physiological groups (I-IV). The classification is based on the ability of the organism to digest complex proteins. Studies at the DNA and rRNA level support the subdivision of the species into groups I-IV. Most outbreaks of human botulism are caused by group I (proteolytic) or II (non-proteolytic) C. botulinum. Group III organisms mainly cause diseases in animals. There has been no record of Group IV C. botulinum causing human or animal disease.
Toxins in food is essential for the following conditions:
1 anaerobic environment there are usually canned and other aerobic microorganisms in a closed container with oxygen consumption is provided. 2 canyon proper temperature for the type A and B reproduced C.botulinum between the 10-12 and the 47-50 °C. Type E psychorotroph known as exposure within 31 to 45 days at 3.3 °C cooling can also produce toxins. Relative humidity, high salt, low-acid, oxygen-free foods and maintained without refrigeration, growth and toxin supports the creation C.botulinum. Using commercial sterilization and pasteurization in combination with other control measures, such as nitrite and salt, as well as the use of vacuum meat from the refrigerator, perishable C.botulinum poisoning can be controlled.
Botulism poisoning can occur due to improperly preserved or home-canned, low-acid food that was not processed using correct preservation times and/or pressure.
Symptoms of botulism
• Double vision • Blurred vision • Drooping eyelid • Slurred speech Difficulty in swallowing • Dry mouth • Muscle weakness • Constipation • Reduced or absent deep tendon reactions, such as tendon, knee Could pass out often Beneficial effects of botulinum toxin Purified botulinum toxin is diluted by a physician for treatment:
- Twitch muscles used
1 - including for the treatment of congenital pelvic tilt 2 - spasmodic dysphasia (the inability of the muscles of the larynx) 3 - achalasia (esophageal stricture) 4 - strabismus (crossed eyes) 5 - paralysis of the facial muscles 6 - Failure of the cervix 7 - Blinking frequently 8 - According to the BBC, an American group is trying Clostridium Type E to deliver anti-cancer drugs directly to the tumor. 
Neurotoxin production is the unifying feature of the species C. botulinum. Eight types of toxins have been identified and allocated a letter (A-H). Most strains produce one type of neurotoxin but strains producing multiple toxins have been described. Clostridium botulinum producing B and F toxin types have been isolated from human botulism cases in New Mexico and California. The toxin type has been designated Bf as the type B toxin was found in excess to the type F. Similarly, strains producing Ab and Af toxins have been reported. There is evidence that the neurotoxin genes have been the subject of horizontal gene transfer, possibly from a viral source. This theory is supported by the presence of integration sites flanking the toxin in some strains of C. botulinum. However, these integrations sites are degraded indicating that the C. botulinum acquired the toxin genes quite far into the evolutionary past.
Only types A, B, E, and F cause disease in humans while types C and D cause disease in cows, birds, and other animals but not in humans. The "gold standard" for determining toxin type is a mouse bioassay, but the genes for types A, B, E, and F can now be readily differentiated using quantitative PCR (PCR).
A few strains from organisms genetically identified as other Clostridium species have caused human botulism: Clostridium butyricum has produced type E toxin and Clostridium baratii had produced type F toxin. The ability of C. botulinum to naturally transfer neurotoxin genes to other clostridia is concerning, especially in the food industry where preservation systems are designed to destroy or inhibit only C. botulinum but not other Clostridium species.
An eighth toxin, type H, was discovered by researchers at the California Department of Public Health in 2013. With a lethal dose of 2 ng by injection or 13 ng by inhalation, it was deemed the most toxic substance on Earth.
|Properties||Group I||Group II||Group III||Group IV|
|Toxin Types||A, B, F||B, E, F||C, D||G|
|Close relatives||C. sporogenes, C. putrificum||C. butyricum, C. beijerinickii||C. haemolyticum, C. novyi type A||C. subterminale, C. haemolyticum|
Clostridium botulinum in different geographical locations
Type A C. botulinum predominates the soil samples from the western regions while type B is the major type found in eastern areas. The type B organisms were of the proteolytic type I. Sediments from the Great Lake regions were surveyed after outbreaks of botulism among commercially reared fish and only type E spores were detected. It has been noted in a survey that type A strains were isolated from soils that were neutral to alkaline (average pH 7.5) while type B strains were isolated from slightly acidic soils (average pH 6.25).
Clostridium botulinum type E is prevalent in aquatic sediments in Norway and Sweden, Denmark, the Netherlands, the Baltic coast of Poland and Russia. It was then suggested that the type E C. botulinum is a true aquatic organism, which was indicated by the correlation between the level of type E contamination and flooding of the land with seawater. As the land dried, the level of type E decreased and type B became dominant.
In soil and sediment from the United Kingdom, C. botulinum type B predominates. In general, the incidence is usually lower in soil than in sediment. In Italy, a survey was conducted in the vicinity of Rome, and a low level of contamination was found; all strains were proteolytic C. botulinum type A or B.
Clostridium botulinum type A was found to be present in soil samples from mountain areas of Victoria. Type B organisms were detected in marine mud from Tasmania. Type A C. botulinum have been found in Sydney suburbs and types A and B were isolated from urban areas. In a well defined area of the Darling-Downs region of Queensland, a study showed the prevalence and persistence of C. botulinum type B after many cases of botulism in horses.
A "mouse protection" or "mouse bioassay" test determines the type of C. botulinum toxin present using monoclonal antibodies. An enzyme-linked immunosorbent assay (ELISA)with digoxigenin-labeled antibodies can also be used to detect the toxin, and quantitative PCR can detect the toxin genes in the organism.
Clostridium botulinum is also used to prepare the medicaments Botox, Dysport, Xeomin, and Neurobloc used to selectively paralyze muscles to temporarily relieve muscle function. It has other "off-label" medical purposes, such as treating severe facial pain, such as that caused by trigeminal neuralgia.
Botulin toxin produced by C. botulinum is often believed to be a potential bioweapon as it is so potent that it takes about 75 nanograms to kill a person (LD50 of 1 ng/kg, assuming an average person weighs ~75 kg); 1 kilogram of it would be enough to kill the entire human population. For comparative purposes, a quarter of a typical grain of sand's weight (350 ng) of botulinum toxin would constitute a lethal dose for humans.
Clostridium botulinum is a soil bacterium. The spores can survive in most environments and are very hard to kill. They can survive the temperature of boiling water at sea level, thus many foods are canned with a pressurized boil that achieves an even higher temperature, sufficient to kill the spores.
Growth of the bacterium can be prevented by high acidity, high ratio of dissolved sugar, high levels of oxygen, very low levels of moisture or storage at temperatures below 3°C (38°F) for type A. For example in a low acid, canned vegetable such as green beans that are not heated hot enough to kill the spores (i.e., a pressurized environment) may provide an oxygen free medium for the spores to grow and produce the toxin. On the other hand, pickles are sufficiently acidic to prevent growth; even if the spores are present, they pose no danger to the consumer. Honey, corn syrup, and other sweeteners may contain spores but the spores cannot grow in a highly concentrated sugar solution; however, when a sweetener is diluted in the low oxygen, low acid digestive system of an infant, the spores can grow and produce toxin. As soon as infants begin eating solid food, the digestive juices become too acidic for the bacterium to grow.
- botulism pathophysiology
- Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K (February 2001). "Botulinum toxin as a biological weapon: medical and public health management". JAMA : the Journal of the American Medical Association285 (8): 1059–70. PMID 11209178.Retrieved on 2012-02-16.
- Doyle, Michael P. (2007). Food Microbiology: Fundamentals and Frontiers. ASM Press. ISBN 1-55581-208-2.
- . (2005). Brock Biology of Microorganisms (11th ed.). Prentice Hall. Unknown parameter
|pinecone isbn=ignored (help)
- E. van Ergmengem. 1897. Über einen neuen anaeroben Bacillus und seine Beziehungen Zum Botulismus. Zentralbl. Hyg. Infektionskr. 26:1–8.
- Frank J. Erbguth. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Movement Disorders. Volume 19, Issue S8, pages S2-S6, March 2004.
- I. A. Bengston. 1924. Studies on organisms concerned as causative factors in botulism. Hyg. Lab. Bull. 136:101
- J. C. Suen, C. L. Hatheway, A. G. Steigerwalt, D. J. Brenner. 1988, Clostridium argentinense sp.nov.: a genetically homogeneous group composed of all strains of Clostridium botulinum type G and some nontoxigenic strains previously identified as Clostridium subterminale or Clostridium hastiforme. Int. J. Sys. Bacteriol. 38:375–381.
- Judicial Commission of the International Committee on Systematic Bacteriology (1999) Rejection of Clostridium putrificum and conservation of Clostridium botulinum and Clostridium sporogenes Opinion 69. International Journal of Systematic Bacteriology. 49:339.
- L. V. Holdeman, J. B. Brooks. 1970. Variation among strains of Clostridium botulinum and related clostridia. Protocols of the first U.S-Japan conference on Toxic Microorganisms. pp. 278–286
- L. D. S. Smith, G. Hobbs. 1974. Genus III Clostridium Prazmowski 1880, 23. In R. E. Buchanan, N. E. gibbons (eds.), Bergey’s Manual of Determinative Bacteriology, 8th edition. William & Wilkins, Baltimore. pp. 551–572.
- Hatheway, C. L., McCroskey, L. M. (1987). "Examination of faeces for diagnosis of infant botulism in 336 patients". J. Clin. Microbiol 25 (12): 2334–2338. PMC 269483. PMID 3323228.
- Satterfield, B. A.; Stewart, A. F.; Lew, C. S.; Pickett, D. O.; Cohen, M. N.; Moore, E. A.; Luedtke, P. F.; O'Neill, K. L. et al. (2010). "A quadruplex real-time PCR assay for rapid detection and differentiation of the Clostridium botulinum toxin genes A, B, E and F". J Med Microbiol 59 (Pt 1): 55–64. doi:10.1099/jmm.0.012567-0. PMID 19779029.
- Aureli, P.; Fenicia, L.; Pasolini, B.; Gianfrancesche, M.; Mccroskey, J. M.; Hatheway, C. L. (1986). "Two cases of type E infant botulism caused by neurotoxigenic Clostridium botulinum in Italy". J. Infect. Dis. 154 (2): 207–211. PMID 3722863.
- Hall, J. D.; McCroskey, L. M.; Pincomb, B. J.; Hatheway, C. L. (1985). "Isolation of an organism resembling Clostridium baratii which produces a type F botulinal toxin from an infant with botulism". J. Clin. Microbiol 21 (4): 654–655. PMC 271744. PMID 3988908.
- Notermans, S., Havellar, A. H. (1980). "Removal and inactivation of botulinum toxin during production of drinking water from surface water". Antonie van Leeuwenhoek 46: 511–514. doi:10.1007/BF00395840.
- MacKenzie, Debora (14 October 2013). "New botox super-toxin has its details censored". NewScientist. Retrieved 15 October 2013.
- A. H. W. Hauschild. 1989. Clostridium botulinum. In M. P. Doyle (ed.), Food-borne Bacterial Pathogens. Marcel Dekker, New York. Pp. 111–189
- Bott, T. L.; Johnson, J.; Foster, E. M.; Sugiyama, H. (1968). "Possible origin of the fish incidences of Clostridium botulinum type E in an inland bay (Green Bay of Lake Michigan)". J. Bacteriol 95: 1542.
- M. W. Eklund, M. E. Peterson, F. T. Poysky, L. W. Peck, J. F. Conrad. 1982. Botulism in juvenile Coho salmon (Onocorhynchus kisutch) in the United States. Aquaculture 27:1–11
- M. W. Eklund, F. T. Poysky M. E. Peterson, L. W. Peck, Brunson. 1984. Type E botulism in salmonids and conditions contributing to outbreaks. Aquaculture 41:293–309.
- A. Johannsen. 1963. Clostridium botulinum in Sweden and the adjacent waters. J. Appl. Bacteriol. 26:43–47.
- Huss, H. H. (1980). "Distribution of Clostridium botulinum". Appl. Environ. Microbiol 39 (4): 764–769. PMC 291416. PMID 6990867.
- Creti, R.; Fenicia, J.; Aureli, P. (1990). "Occurrence of Clostridium botulinum in the soil of the vicinity of Rome". Curr. Microbiol 20: 317.
- C. E. Eales, J. M. Gillespie. 1947. the isolation of Clostridium botulinum type A from Victorian soils. Aust. J. Sci. 10:20–21.
- D. f. Ohye, W. J. Scott. 1957. Studies in the physiology of Clostridium botulinum type E. Aust. L. Biol. Sci. 10:85–94.
- Shashi K. Sharma, Joseph. L. Ferreira, Brian S. Eblen and Richard C. Whitingand. Detection of Type A, B, E, and F Clostridium botulinum Neurotoxins in Foods by Using an Amplified Enzyme-Linked Immunosorbent Assay with Digoxigenin-Labeled Antibodies. Appl. Environ. Microbiol. February 2006 vol. 72 no. 2 1231-1238. doi:10.1128/AEM.72.2.1231-1238.2006
- Fleming, Diane O. "Biological Safety: principles and practices". ASM Press 2000: 267.